Originally published June 29 2006
New Study Links Second Hand Smoke to Allergy Risk for Infants; Nymox (NASDAQ:NYMX) TobacAlert(TM) Product Detects Second-Hand Smoke Exposure (press release)
Nymox Pharmaceutical's (NASDAQ:NYMX) TobacAlert(TM) product allows for an easy-to-use, cost-effective
means of on-site testing for second-hand smoke exposure without the need for instruments, equipment or specialized training. Heavy exposure to second-hand smoke at home nearly tripled the risk that an infant will develop allergic rhinitis by age 1, according to a new study of 633 infants by researchers from the University of Cincinnati and the Children's Hospital Medical Center in Cincinnati (Pediatr Allergy Immunol 2006 online early issue). Rhinitis is caused by inflammation of the nasal membranes, leading to symptoms such as nasal congestion, sneezing and a runny or itchy nose. Allergic rhinitis in the infants was confirmed by a positive skin prick test to an airborne allergen.
Second-hand smoke exposure can have serious health consequences for infants and children, including sudden infant death syndrome (SIDS), cause and exacerbation of asthma, increased respiratory tract infections, increased middle ear infections, low birth weight, and developmental impacts. Exposure to second-hand smoke in the home during childhood has also been linked to elevated risk of lung cancer in adults.
TobacAlert(TM) measures levels of cotinine, a metabolite of nicotine widely used to detect second-hand smoke exposure. More information is available at www.tobacalert.com. More information about Nymox is available at www.nymox.com, email: [email protected], or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml